Does elevated myeloperoxidase promote LDL oxidation and endothelial dysfunction?

Myeloperoxidase (MPO) serves as a potent enzymatic driver of vascular inflammation and oxidative stress. Secreted by activated neutrophils and monocytes, it acts as a critical link between inflammation and the development of atherosclerosis, particularly in populations at higher cardiovascular risk, such as post-menopausal women.

Clinical and effectiveness evidence

Elevated MPO levels are a validated indicator of systemic oxidative enzyme activity and provide significant prognostic value for cardiovascular risk.

• Cardiovascular Risk Prediction: Clinical studies have established that elevated serum MPO independently predicts endothelial dysfunction, often measured via impaired flow-mediated dilation (FMD). In large-scale cohorts, higher MPO concentrations have been associated with an increased risk of future coronary artery disease (CAD) and acute coronary syndromes.
• Aging and Inflammation: In the context of aging, such as in a 71-year-old female, MPO activity is often intensified due to a higher baseline of systemic inflammation (inflammaging). This heightened activity correlates with other markers of oxidative damage, including malondialdehyde (MDA) and reduced glutathione (GSH) imbalance.

Mechanistic explanations

MPO promotes vascular damage through three primary biochemical pathways:

• Production of Potent Oxidants: MPO catalyzes the reaction between hydrogen peroxide and chloride ions to produce hypochlorous acid (HOCl). This highly reactive oxidant causes widespread damage to proteins and lipids.
• LDL Oxidation: MPO binds directly to the apolipoprotein B-100 (ApoB-100) on LDL particles. This physical association can increase MPO's enzymatic activity by up to 90%, facilitating the generation of pro-atherogenic oxidized LDL (Mox-LDL). Mass spectrometry has confirmed the presence of MPO-specific modifications, such as chlorotyrosine, within human atherosclerotic lesions.
• Nitric Oxide Depletion: MPO directly consumes nitric oxide (NO), the molecule responsible for vasodilation. By limiting NO bioavailability and inhibiting endothelial nitric oxide synthase (eNOS), MPO increases arterial stiffness and impairs the ability of blood vessels to relax.

Clinical implications

The role of MPO in driving endothelial dysfunction is further validated by experimental models where the inhibition of MPO activity restores endothelial integrity and improves nitric oxide signaling. For older patients, managing MPO-related oxidative stress is crucial for maintaining microvascular health and reducing the burden of subclinical atherosclerosis.

Bottom line

Elevated myeloperoxidase is a primary driver of vascular disease that promotes LDL oxidation and endothelial dysfunction by depleting nitric oxide and generating potent oxidants like hypochlorous acid. These processes directly contribute to the formation of atherosclerotic plaques and impaired vascular reactivity.